# HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma

Source: https://onco.cc/trials/nct04353375/  
OnCo record `nct04353375` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial testing HMPL-453 in biliary tract cancer, now recruiting.

## Summary

HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma is a phase 2/3 interventional study registered as NCT04353375, led by Hutchmed, and recruiting on the registry. Official title: An Open-Label, Single-Arm, Multicenter Phase 2/3b Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HMPL-453 Tartrate in Patients With Advanced Intrahepatic Cholangiocarcinoma Habouring FGFR2 Fusion/Rearrangement. Planned enrolment is 235 participants (estimated). The study started in 2020-09-03 and primary completion is expected in 2028-06-30. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT04353375
- Phase: 2/3
- Setting: An Open-Label, Single-Arm, Multicenter Phase 2/3b Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HMPL-453 Tartrate in Patients With Advanced Intrahepatic Cholangiocarcinoma Habouring FGFR2 Fusion/Rearrangement
- Sponsor: Hutchmed
- Enrolled: 235

## Sources

- ClinicalTrials.gov NCT04353375: https://clinicaltrials.gov/study/NCT04353375

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/)
- drugs: [HMPL-453](https://onco.cc/drugs/hmpl-453/)
- companies: [Hutchmed](https://onco.cc/companies/hutchmed/)

---
JSON: https://onco.cc/api/v1/entities/nct04353375.json